Physician profile
Abigail Grace Ward
NPI 1528578846
$2,059.47
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $329 · 2023: $762 · 2024: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $571.39 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $463.29 | 2021-2024 | Airsupra, Fasenra, Tezspire |
| Alk-Abello, INC | $211.79 | 2022-2023 | Grastek, Odactra, Timothy, Standardized |
| Glaxosmithkline, LLC. | $196.12 | 2021-2024 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $126.61 | 2022-2024 | Dupixent |
| Octapharma USA, INC. | $94.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $89.21 | 2021-2023 | Airduo Digihaler |
| Biocryst US Sales Co., LLC | $50.76 | 2021-2023 | Orladeyo |
| Kaleo, INC. | $50.15 | 2021-2023 | Auvi-Q |
| Csl Behring | $47.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.82 | 2023 | |
| Genentech USA, INC. | $24.89 | 2024 | Xolair |
| Aimmune Therapeutics, INC. | $22.17 | 2022 | |
| Optinose US, INC. | $20.02 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.76 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.25 | 2021 | |
| Mylan Specialty L.P. | $14.00 | 2023 | Yupelri |
| Abbvie INC. | $13.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.